Private Equity

Investment in Carbon Capture and Storage

Although carbon emissions occupy a relatively small space on the spectrum of environmental, social and governance issues, as more and more countries and companies commit to Net Zero, they are steadily gaining attention from investors. Companies have relied on offsets to help avoid or reduce emissions for decades. Long associated with the “cap and trade” […]


Strategies That Chinese Small and Medium-Sized Enterprises Use to Attract Venture Capital

Abstract Small and medium-sized enterprises (SMEs) contribute to China’s economic growth and help maintain social stability. However, SME business leaders have cited access to finance as an obstacle of SMEs’ survival and success. The purpose of this multiple case study was to identify main strategies SME entrepreneurs and business leaders used to attract venture capital […]

Private Equity Market Landscape – First Quarter 2014

The year of 2013 has been the most successful year for private equity firms since 2008, with 873 funds with an aggregate of $454 billion. In 2013, the private equity-backed buyout market was particularly strong; a total of 1,348 buyout exits were valued at $303 billion. Global merger and acquisition activity was dominated by a […]

Venture Capital in Life Sciences (III): Monoclonal Antibodies in the Treatment of Ankylosing Spondylitis

The application of monoclonal antibody drugs is a relatively new innovation. Approximately 54% of monoclonal antibody drugs available are applied in various types of cancer, although clinical trials are also studying monoclonal drugs in autoimmune diseases, and sex organ transplants. When a monoclonal antibody attaches to a cancer cell, it can make the cancer cell […]

Venture Capital in Life Sciences (II): Pharmacogenomics and Personalized Medicine

Pharmacogenomics focuses on understanding the response rates and side effects of a treatment at the individual level. It analyzes the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with the efficacy or toxicity of a drug, hence improves clinical outcomes. The field of pharmacogenomics has applied in […]